Valuation: Erasca, Inc.

Market Cap 5.32B 4.78B 4.42B 4B 7.47B 507B 7.56B 52.8B 21.03B 265B 19.98B 19.55B 842B P/E 2026 *
-15.4x
P/E 2027 * -23.2x
Enterprise Value 4.47B 4.01B 3.71B 3.36B 6.28B 426B 6.36B 44.38B 17.68B 223B 16.79B 16.44B 708B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week+2.59%
Current month+1.40%
1 month+5.20%
3 months-18.14%
6 months+50.15%
Current year+299.60%
1 week 13.44
Extreme 13.44
15.47
1 month 13.1
Extreme 13.1
16.2
Current year 3.36
Extreme 3.36
24.28
1 year 2.1
Extreme 2.105
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer 66 10/08/2026
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/6/26 Free

Director

29,888 0.0096%
1/4/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-2.27%+2.59%+509.22%+572.62% 5.32B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+2.42%+0.56%+27.53%+57.02% 44.75B
+2.25%-3.17%+18.10%+100.52% 41.62B
+0.17%-4.02%+220.56%+916.19% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +3.73%+0.03%+97.43%+202.80% 38.58B
Weighted average by Cap. +3.01%-0.23%+53.50%+166.10%

Financials

2026 *2027 *
Net sales - -
Net income -322M -289M -267M -242M -452M -30.65B -457M -3.19B -1.27B -16.04B -1.21B -1.18B -50.91B -228M -205M -189M -171M -320M -21.73B -324M -2.26B -901M -11.37B -856M -838M -36.1B
Net Debt -849M -761M -704M -637M -1.19B -80.82B -1.21B -8.42B -3.35B -42.29B -3.18B -3.12B -134B -762M -683M -632M -572M -1.07B -72.55B -1.08B -7.55B -3.01B -37.96B -2.86B -2.8B -121B
Projected Income Statement - Annual - Erasca, Inc.
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
29/10/26 USD 14.90 -2.10% 1,628,868
27/10/26 USD 15.22 +1.53% 5,825,747
26/10/26 USD 14.99 +4.17% 6,466,122
23/10/26 USD 14.39 +2.49% 3,499,957
22/10/26 USD 14.04 -3.11% 2,296,073
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Erasca, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.22USD
Average target price
24.11USD
Spread / Average Target
+58.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Erasca, Inc.
  1. Stock Market
  2. Stocks
  3. ERAS Stock